Business Today
Generic semaglutide launches have expanded access and pushed India's GLP-1 market close to Rs 2,000 crore. But as the initial rush fades, companies face a tougher challenge of finding new obesity patients and keeping them on treatment.
Go to News Site
Zee News
India Today
The Hindu
भारत समाचार
India Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today
Business Today